AU2003255482A1 - Use of 4 amino-quinazolines as anti cancer agents - Google Patents

Use of 4 amino-quinazolines as anti cancer agents

Info

Publication number
AU2003255482A1
AU2003255482A1 AU2003255482A AU2003255482A AU2003255482A1 AU 2003255482 A1 AU2003255482 A1 AU 2003255482A1 AU 2003255482 A AU2003255482 A AU 2003255482A AU 2003255482 A AU2003255482 A AU 2003255482A AU 2003255482 A1 AU2003255482 A1 AU 2003255482A1
Authority
AU
Australia
Prior art keywords
quinazolines
amino
cancer agents
anti cancer
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003255482A
Inventor
Gerhard Barnickel
Hans-Michael Eggenweiler
Volker Eiermann
Rolf Gericke
Wilfried Rautenberg
Burkhard Scharm
Christian Sirrenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2003255482A1 publication Critical patent/AU2003255482A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
AU2003255482A 2002-10-02 2003-08-25 Use of 4 amino-quinazolines as anti cancer agents Abandoned AU2003255482A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02022151.1 2002-10-02
EP02022151 2002-10-02
PCT/EP2003/009392 WO2004030672A1 (en) 2002-10-02 2003-08-25 Use of 4 amino-quinazolines as anti cancer agents

Publications (1)

Publication Number Publication Date
AU2003255482A1 true AU2003255482A1 (en) 2004-04-23

Family

ID=32049971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003255482A Abandoned AU2003255482A1 (en) 2002-10-02 2003-08-25 Use of 4 amino-quinazolines as anti cancer agents

Country Status (2)

Country Link
AU (1) AU2003255482A1 (en)
WO (1) WO2004030672A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000409A1 (en) 2003-03-03 2005-01-07 Vertex Pharma COMPOUNDS DERIVED FROM 2- (REPLACED CILO) -1- (AMINO OR REPLACED OXI) -CHINAZOLINE, INHIBITORS OF IONIC SODIUM AND CALCIUM VOLTAGE DEPENDENTS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF ACUTE PAIN, CHRONIC, NEU
US7713983B2 (en) 2003-03-03 2010-05-11 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
EP1610774A4 (en) * 2003-04-09 2008-07-16 Exelixis Inc Tie-2 modulators and methods of use
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
US7928107B2 (en) 2004-09-02 2011-04-19 Vertex Pharmaceuticals Incorporated Quinazolines useful as modulators of ion channels
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
WO2007065913A1 (en) * 2005-12-07 2007-06-14 Neurosearch A/S Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
JP2009534458A (en) 2006-04-26 2009-09-24 キャンサー・リサーチ・テクノロジー・リミテッド Amino-ethyl-amino-aryl (AEAA) compounds and their use
WO2008124823A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Method of treating melanoma
EP2241565A1 (en) * 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
CA2772642C (en) 2009-09-03 2017-08-29 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
JP5792171B2 (en) * 2009-09-04 2015-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating leukemia
CN102574817A (en) 2009-09-24 2012-07-11 巴斯夫欧洲公司 Aminoquinazoline compounds for combating invertebrate pests
AU2011249859B2 (en) 2010-05-07 2014-07-03 California Institute Of Technology Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
WO2013013614A1 (en) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof
TWI547494B (en) * 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
US9458131B2 (en) 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
EP2875015A1 (en) * 2012-07-23 2015-05-27 Merck Patent GmbH Ligands and their preparation
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
WO2014128622A1 (en) * 2013-02-21 2014-08-28 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
CN104130200B (en) * 2014-07-01 2016-04-20 中山大学 A kind of 2-substituted-phenyl-4-aryl amine quinazoline derivant and its preparation method and application
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
JP2018509378A (en) * 2014-12-05 2018-04-05 サウザーン リサーチ インスチチュート Novel quinazolines as biogenic amine transport modulators
JP6356919B2 (en) 2014-12-24 2018-07-11 ギリアード サイエンシーズ， インコーポレイテッド Isoquinoline compounds for the treatment of HIV
TW202237569A (en) 2014-12-24 2022-10-01 美商基利科學股份有限公司 Quinazoline compounds
MX2017008520A (en) 2014-12-24 2018-03-01 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv.
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI703150B (en) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 Methods and compositions for inhibiting the interaction of menin and mll proteins
BR112018068702A2 (en) 2016-03-16 2019-01-15 Kura Oncology Inc menin-mll bridged bicyclic inhibitors and methods of use
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CA3046997A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018187615A1 (en) * 2017-04-05 2018-10-11 Curza Global, Llc Compositions and methods comprising a triaryl polyamine
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
JP2020530000A (en) * 2017-08-02 2020-10-15 ノースウエスタン ユニバーシティ Substituent condensation pyrimidine compounds and their use
TW201920170A (en) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted inhibitors of MENIN-MLL and methods of use
CA3188260A1 (en) * 2020-08-07 2022-02-10 Dimitrios Iliopoulos Small molecules for the treatment of autoimmune diseases and cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR012634A1 (en) * 1997-05-02 2000-11-08 Sugen Inc QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE
DE19756388A1 (en) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh New 2-aryl-4-amino-6,7-di:methoxy-quinazoline derivatives useful as guanylate cyclase activators for treating cardiovascular diseases, etc.
US20020025968A1 (en) * 1998-04-15 2002-02-28 Rifat Pamukcu Method for inhibiting neoplastic cells and related conditions by exposure to 4-aminoquinazoline derivatives
JP2003504363A (en) * 1999-07-09 2003-02-04 グラクソ グループ リミテッド Anilinoquinazolines as protein tyrosine kinase inhibitors
JP2004509875A (en) * 2000-09-20 2004-04-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 4-aminoquinazoline
BR0116411A (en) * 2000-12-21 2003-11-11 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors

Also Published As

Publication number Publication date
WO2004030672A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
AU2003255482A1 (en) Use of 4 amino-quinazolines as anti cancer agents
WO2003073826A8 (en) Novel compositions and methods for cancer
HK1086488A1 (en) Compound and use thereof for the treatment of cancer
AUPS146402A0 (en) Nanofiller compositions
AU2003211453A1 (en) External compositions for the skin
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2003258662A1 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2003246083A1 (en) Ferrocene compound and use thereof
AU2003227489A1 (en) Skin protecting compositions
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
AU2003275505A1 (en) Electowinning of metals
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2002334891A1 (en) Tumor targeted photodiagnostic-phototherapeutic agents
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003224826A1 (en) Endohedral metallofullerene contrast agents
AU2004281077A1 (en) Methods and agents for the treatment of cancer
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2003257651A1 (en) 4'-thionucleotide
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
WO2005042707A9 (en) Taspasel 1 and methods of use
AU2003238034A1 (en) Novel use of imidazotriazinones

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase